CSL buys gene therapy treatment for haemophilia
Biotechnology company CSL has completed the acquisition of a novel gene therapy for the treatment of haemophilia B from NASDAQ listed uniQure. The company will pay US$450 million initially with further milestone payments and royalties to follow as the product etranacogene dezaparvovec (AMT-061) is further developed and commercialised. uniQure will complete the Phase three trial…